In Vivo and In Vitro Chemical Synthetic Lethality of ABHD17 and MEK Inhibition in NRAS -Mutant Acute Myeloid Leukemia. Read more about In Vivo and In Vitro Chemical Synthetic Lethality of ABHD17 and MEK Inhibition in NRAS -Mutant Acute Myeloid Leukemia.
HLA-Pan-DP CAR-T Demonstrates Cytotoxicity Against Multiple Hematological Malignancies. Read more about HLA-Pan-DP CAR-T Demonstrates Cytotoxicity Against Multiple Hematological Malignancies.
Effective Azacytidine Monotherapy in an Infant with Mosaic NRAS-Driven JMML. Read more about Effective Azacytidine Monotherapy in an Infant with Mosaic NRAS-Driven JMML.
Preclinical Activity of RAS(ON) Multi-Selective Inhibitor RMC-7977 and Therapeutic Combinations in AML with Signaling Mutations. Read more about Preclinical Activity of RAS(ON) Multi-Selective Inhibitor RMC-7977 and Therapeutic Combinations in AML with Signaling Mutations.
AML Derived Induced Pluripotent Stem Cells Reveal a Genotype-Independent Effect of Monocytic Differentiation in Mediating Venetoclax Resistance. Read more about AML Derived Induced Pluripotent Stem Cells Reveal a Genotype-Independent Effect of Monocytic Differentiation in Mediating Venetoclax Resistance.
Identification of High-Efficiency ß-Catenin Protein Degradation As Critical Vulnerability in B-Cell Malignancies. Read more about Identification of High-Efficiency ß-Catenin Protein Degradation As Critical Vulnerability in B-Cell Malignancies.
Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL). Read more about Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL).
Thirdhand Smoke As a Risk Factor for Pediatric Lymphoblastic Leukemia: Accelerated Leukemia in Female Pax5-P80R Mice. Read more about Thirdhand Smoke As a Risk Factor for Pediatric Lymphoblastic Leukemia: Accelerated Leukemia in Female Pax5-P80R Mice.
Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2). Read more about Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2).
Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Read more about Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium
